Dyadic International Inc. (NASDAQ:DYAI) Short Interest Up 97.7% in March

Dyadic International Inc. (NASDAQ:DYAI) saw a significant growth in short interest during the month of March. As of March 31st, there was short interest totaling 130,008 shares, a growth of 97.7% from the March 15th total of 65,770 shares. Approximately 0.5% of the shares of the company are short sold. Based on an average daily trading volume, of 139,342 shares, the days-to-cover ratio is presently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a report on Friday, March 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Dyadic International Stock Performance

DYAI stock traded down $0.02 on Monday, reaching $0.87. The company’s stock had a trading volume of 4,360 shares, compared to its average volume of 63,530. Dyadic International has a 52 week low of $0.65 and a 52 week high of $1.35. The company has a market capitalization of $31.70 million, a P/E ratio of -3.48 and a beta of 1.21. The firm has a fifty day moving average of $0.82 and a two-hundred day moving average of $0.93. The company has a debt-to-equity ratio of 4.08, a current ratio of 2.68 and a quick ratio of 2.68.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.03). Dyadic International had a negative net margin of 239.67% and a negative return on equity of 695.96%. The business had revenue of $0.57 million for the quarter, compared to the consensus estimate of $1.34 million. As a group, analysts predict that Dyadic International will post -0.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyadic International

Large investors have recently bought and sold shares of the stock. Marathon Capital Management bought a new stake in shares of Dyadic International during the 3rd quarter worth about $41,000. Bank of America Corp DE raised its holdings in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. acquired a new stake in Dyadic International in the third quarter worth approximately $190,000. Geode Capital Management LLC boosted its stake in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 36,266 shares in the last quarter. Finally, Truist Financial Corp increased its position in shares of Dyadic International by 30.5% during the 3rd quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after purchasing an additional 76,200 shares during the period. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.